ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Alto Neuroscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$22.82+0.88 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $976.99M
- P/E (TTM)
- –
- Dividend yield
- –
Alto Neuroscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Market Cap | $895.51M | $166.30M |
| Enterprise Value | $667.96M | $88.19M |
| PB Ratio | 4.08 | 2.03 |
| P/TBV Ratio | 4.08 | 2.29 |
Income (trailing twelve months)
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Operating Income | -$88.27M | -$21.40M |
| Net Income | -$84.24M | -$22.46M |
| EBITDA | -$88.27M | -$16.91M |
| EPS (Diluted) | -$2.44 | -$0.83 |
Returns
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -49.2% | -53.2% |
| Return on Assets (ROA) | -40.9% | -40.9% |
| Return on Capital Employed (ROCE) | -37.2% | -38.1% |
Balance sheet
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $243.73M | $61.43M |
| Total Debt | $16.19M | $118.52M |
| Net Cash (Debt) | $227.55M | $15.35M |
| Net Cash Per Share | $5.80 | $0.66 |
| Equity (Book Value) | $219.25M | $49.09M |
| Book Value Per Share | $5.59 | $1.37 |
| Tangible Book Value | $219.25M | $23.52M |
| Working Capital | $230.67M | $76.81M |
Financial position
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Current Ratio | 14.85 | 3.34 |
| Quick Ratio | 14.64 | 2.44 |
| Debt / Equity | 0.07 | 0.52 |
| Interest Coverage | -39.04 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$68.29M | -$12.35M |
| Capital Expenditures | -$556.00K | -$1.08M |
| Free Cash Flow | -$68.84M | -$20.22M |
| FCF Per Share | -$1.75 | -$0.42 |
Efficiency
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Profits Per Employee | -$1.24M | -$703.34K |
| Employee Count | 68 | 74 |
Dividends and yields
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Earnings Yield | -9.41% | -23.3% |
| FCF Yield | -7.69% | -8.72% |
Shares
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Shares Outstanding | 39,242,100 | 58,127,000 |
| Shares Change (YoY) | 27.0% | 10.9% |
| Shares Change (QoQ) | 0.12% | 0.54% |
| Float | 37,104,200 | 49,136,700 |
| Shares Held by Insiders | 5.45% | 11.6% |
| Shares Held by Institutions | 75.1% | 59.4% |
Scores
| Measure | Alto Neuroscience | Industry median |
|---|---|---|
| Altman Z-Score | 13.97 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Alto Neuroscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.